Abivax
5, rue de la Baume
Paris
75008
France
Tel: 33-0-1-53-83-08-41
Website: http://www.abivax.com/en/
Email: info@abivax.com
169 articles about Abivax
-
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)
2/13/2024
Abivax SA announced that four scientific abstracts on its lead drug candidate, obefazimod for the treatment of moderately to severely active ulcerative colitis, will be presented during the 19th Congress of the European Crohn's and Colitis Organisation on February 21-24, 2024, in Stockholm, Sweden.
-
Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
1/24/2024
Abivax SA announces the organization of a virtual KOL Investor Event on Tuesday, February 6, 2024, at 2:00 p.m. EST.
-
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
1/22/2024
Abivax SA, a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, provides an outlook on its 2024 strategic priorities and milestones.
-
Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market
10/24/2023
Abivax SA today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares (the " New Shares "), consisting of a public offering of 18,699,460 ordinary shares in the form of American Depositary Shares (" ADSs ").
-
Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market
10/20/2023
Abivax SA announced today the pricing of its initial public offering on the Nasdaq Global Market by way of a capital increase of 20,325,500 new ordinary shares.
-
Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
10/20/2023
Abivax SA announced the trading resumption of its ordinary shares on Euronext in Paris as from 4:20 p.m. CEST.
-
Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris
10/20/2023
Abivax SA announced that trading of its ordinary shares on the regulated market of Euronext in Paris will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m. CEST.
-
Abivax Announces the Filing of an Amended Registration Statement, Including an Estimated Initial Public Offering Price Range
10/18/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company") today announced the formal commencement of book-building and the filing of an amended registration statement on Form F-1, including an estimated initial public offering price range, in connection with its intention to issue, subject to market and other conditions, approximately 20,325,500 ordinary shares.
-
Abivax Announces the Start of the Roadshow for its Proposed Global Offering and Proposed Nasdaq Listing
10/16/2023
Abivax SA announced the start of its roadshow in connection with its intention to issue, subject to market and other conditions, 18,675,500 ordinary shares of the Company in an initial public offering of American Depositary Shares, each representing one ordinary share, in the United States and a concurrent offering of ordinary shares in certain jurisdictions outside of the United States.
-
Abivax Highlights Obefazimod Ulcerative Colitis Program With New Data to be Presented at the UEG Week 2023
10/2/2023
Abivax SA (Euronext Paris:FR0012333284 - ABVX) ("Abivax" or the "Company") today announced that three scientific abstracts on its lead drug candidate, obefazimod, will be presented during the United European Gastroenterology (UEG) Week meeting, October 14-17, 2023, in Copenhagen, Denmark.
-
Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.
-
Abivax presents first-half 2023 financial results
9/21/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announces today its 2023 half-year financial results, as of June 30, 2023.
-
Abivax Appoints Patrick Malloy as Senior Vice President Investor Relations
8/23/2023
Abivax SA announced the appointment of Patrick Malloy as new Senior Vice President Investor Relations.
-
Abivax Secures Up to EUR 150M from Two Structured Debt Financing Transactions
8/21/2023
Abivax SA announced that it has concurrently signed two structured debt financing transactions for a total amount of up to EUR 150M consisting of up to EUR 75M from Kreos Capital and Claret European Growth Capital together with the issuance of warrants exercisable to receive up to EUR 8M worth of ordinary shares of the Company, par value of EUR 0.01 per share, and up to EUR 75M from a fund advised by Heights Capital Management, Inc..
-
Abivax Announces Plans to Conduct Registered Public Offering in the United States
8/10/2023
Abivax SA announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares, in the United States, subject to market and other conditions, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission.
-
Abivax Announces the Appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors
7/11/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces today the appointment of June Lee, M.D. and Troy Ignelzi as new independent members of the Abivax Board of Directors.
-
Abivax receives "Capital Market Transaction of the Year Award" at the European Mediscience Awards 2023
6/15/2023
Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces that it received the "Capital Market Transaction of the Year Award" at the European Mediscience Awards 2023.
-
Abivax Releases the Results of its June 5, 2023 Ordinary and Extraordinary General Meeting
6/8/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX) held its ordinary and extraordinary general meeting of shareholders on June 5, 2023, which was chaired by Marc de Garidel, CEO of Abivax and interim Chairman of the Board of Directors.
-
Abivax Appoints Ida Hatoum as Chief People Officer
6/8/2023
Abivax SA (Euronext Paris: FR0012333284 - ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, today announces the appointment of Ida Hatoum as Chief People Officer.
-
Abivax Stock Included in MSCI Indexes
6/8/2023
Abivax, a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with chronic inflammatory diseases, announces that as of June 1 st, 2023, its stock is represented in the MSCI Indexes.